Genmab — Oktober 2017
-
Genmab har været "fanget" af JJ. For JJ er det her ikke engang en afrunding og Genmab har ikke ret til at udtale sig om omsætningen
-
JV tak, enig i at de 107 er de reelle salgstal..de 122 var fiktive i forhold til q1-2 for at kunne beregne udruldningen.
-
Men det er voldsomt uheldigt. Tallene viser total flatlining, men den reelle vækst er 40-45% q/q
-
Jeg fik købt til kurs 1293... godt tilfreds
-
3 dage ud af 20 (ca.) = 15%, så det er vel ikke dårligt?
-
Jeg begynder at forstå udlandets reaktion på Q3. Vi retail investorer er virkelig langt bagud på point ifht de professionelle
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind